Aprea Therapeutics (APRE) vs Curanex Pharmaceuticals (CURX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($8.3 million vs $7.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | CURX |
|---|---|---|
| Share price | $0.6044 | $5.31 |
| Market cap | $7.61M | $8.33M |
| 1-day change | +8.28% | +11.55% |
| EPS (TTM) | $-0.95 | $-7.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $16.94 |
| 52-week low | $0.548 | $3.58 |
| Distance from 52-week high | -64.24% | -68.65% |
| Analyst consensus | none | — |
| Avg. price target upside | +517.14% | — |
| Average volume | 280.14K | 19.85K |
| Shares outstanding | 12.59M | 1.57M |
| Employees | 8 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
APRE vs CURX FAQ
Which is bigger, Aprea Therapeutics or Curanex Pharmaceuticals?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $8.33M compared with $7.61M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and Curanex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.